Institute for Science and Technology in Medicine, Keele University, Stoke on Trent, United Kingdom;
J Am Soc Nephrol. 2013 Dec;24(12):2071-80. doi: 10.1681/ASN.2013030314. Epub 2013 Sep 5.
Systemic inflammation, as evidenced by elevated inflammatory cytokines, is a feature of advanced renal failure and predicts worse survival. Dialysate IL-6 concentrations associate with variability in peritoneal small solute transport rate (PSTR), which has also been linked to patient survival. Here, we determined the link between systemic and intraperitoneal inflammation with regards to peritoneal membrane function and patient survival as part of the Global Fluid Study, a multinational, multicenter, prospective, combined incident and prevalent cohort study (n=959 patients) with up to 8 years of follow-up. Data collected included patient demographic characteristics, comorbidity, modality, dialysis prescription, and peritoneal membrane function. Dialysate and plasma cytokines were measured by electrochemiluminescence. A total of 426 survival endpoints occurred in 559 incident and 358 prevalent patients from 10 centers in Korea, Canada, and the United Kingdom. On patient entry to the study, systemic and intraperitoneal cytokine networks were dissociated, with evidence of local cytokine production within the peritoneum. After adjustment for multiple covariates, systemic inflammation was associated with age and comorbidity and independently predicted patient survival in both incident and prevalent cohorts. In contrast, intraperitoneal inflammation was the most important determinant of PSTR but did not affect survival. In prevalent patients, the relationship between local inflammation and membrane function persisted but did not account for an increased mortality associated with faster PSTR. These data suggest that systemic and local intraperitoneal inflammation reflect distinct processes and consequences in patients treated with peritoneal dialysis, so their prevention may require different therapeutic approaches; the significance of intraperitoneal inflammation requires further elucidation.
全身性炎症,表现为炎症细胞因子升高,是晚期肾衰竭的特征,并预示着更差的生存。透析液中白细胞介素 6(IL-6)浓度与腹膜小分子转运率(PSTR)的变化相关,而 PSTR 也与患者的生存相关。在这里,我们在全球液体研究(Global Fluid Study)中确定了全身性和腹腔内炎症与腹膜功能和患者生存之间的联系,该研究是一项多中心、前瞻性、联合发病和流行队列研究,涉及多国,共纳入了 959 名患者,随访时间长达 8 年。收集的数据包括患者的人口统计学特征、合并症、治疗方式、透析方案和腹膜功能。通过电化学发光法测量透析液和血浆细胞因子。在韩国、加拿大和英国的 10 个中心,共有 426 名生存终点发生在 559 名新发病例和 358 名现患患者中。在患者进入研究时,全身性和腹腔内细胞因子网络是分离的,腹膜内存在局部细胞因子产生的证据。在调整了多个协变量后,全身性炎症与年龄和合并症相关,并独立预测了新发病例和现患患者的生存。相比之下,腹腔内炎症是 PSTR 的最重要决定因素,但对生存没有影响。在现患患者中,局部炎症与膜功能之间的关系仍然存在,但不能解释与更快的 PSTR 相关的死亡率增加。这些数据表明,接受腹膜透析治疗的患者的全身性和局部腹腔内炎症反映了不同的过程和后果,因此预防可能需要不同的治疗方法;局部炎症的意义需要进一步阐明。